Related Experiment Video

Updated: Apr 20, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties

Sara Ibrahim Omar1, Jack Tuszynski1,2

  • 1Department of Oncology, University of Alberta, Edmonton, AB, Canada, T6G 1Z2.

Chemical Biology & Drug Design
|November 20, 2014
PubMed

Insights

Restoring tumor suppressor p53 function in cancer cells shows promise. This study docked p53 activators, revealing stictic acid as a potential candidate with fewer adverse effects but needing pharmacokinetic improvements.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The tumor suppressor protein p53 is frequently mutated in cancer.
  • Restoring wild-type p53 activity is a therapeutic strategy for cancer.
  • The mechanism of action for mutant p53 activators is not fully understood.

Purpose of the Study:

  • To investigate the binding mechanisms of known p53 activators.
  • To identify potential p53-restoring drug candidates.
  • To predict the drug-like properties of these activators.

Main Methods:

  • Molecular docking of twelve known p53 activators into a transiently open pocket of mutant p53.
  • Prediction of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties.
  • Analysis of ligand binding sites and interactions, including with Cys124.

Main Results:

  • Ligand binding positions varied, particularly for alkylating agents, likely due to size differences.
  • Non-alkylating ligands were found to bind within the same pocket and interact with Cys124.
  • Stictic acid showed potential as a p53 activator with a favorable safety profile but suboptimal pharmacokinetics.

Conclusions:

  • Understanding ligand interactions with mutant p53 can guide the development of novel cancer therapies.
  • Stictic acid warrants further investigation as a potential therapeutic agent for p53-mutated cancers.
  • Pharmacokinetic optimization is necessary for stictic acid to maximize its therapeutic utility.
Keywords:
ADMET propertiesMD simulationsP53 activatorsdockingp53-R273H

More Related Videos

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy06:38

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy

Published on: February 7, 2019

9.3K
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

357

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
10.0K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
6.0K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.3K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
7.0K